Atara Biotherapeutics, Inc. – NASDAQ:ATRA
Atara Biotherapeutics stock price today
$12
-0.15
-1.24%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 16 hours
Atara Biotherapeutics stock price monthly change
+16.05%
month
Atara Biotherapeutics stock price quarterly change
+16.05%
quarter
Atara Biotherapeutics stock price yearly change
+2070.03%
year
Atara Biotherapeutics key metrics
Market Cap | 67.38M |
Enterprise value | 229.27M |
P/E | -1.16 |
EV/Sales | 3.61 |
EV/EBITDA | -1.04 |
Price/Sales | 4.16 |
Price/Book | 2.08 |
PEG ratio | -0.03 |
EPS | -2.13 |
Revenue | 34.70M |
EBITDA | -212.91M |
Income | -233.10M |
Revenue Q/Q | 2131.40% |
Revenue Y/Y | -39.62% |
Profit margin | -360.37% |
Oper. margin | -442.78% |
Gross margin | 81.42% |
EBIT margin | -442.78% |
EBITDA margin | -613.52% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAtara Biotherapeutics stock price history
Atara Biotherapeutics stock forecast
Atara Biotherapeutics financial statements
Average Price Target
$14
Potential upside: 16.66%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 957K | -71.10M | -7430.3% |
|---|---|---|---|
| Sep 2023 | 2.13M | -69.79M | -3264.59% |
| Dec 2023 | 4.25M | -60.45M | -1421.68% |
| Mar 2024 | 27.35M | -31.75M | -116.07% |
| Jun 2023 | 246439000 | 238.98M | 96.98% |
|---|---|---|---|
| Sep 2023 | 188788000 | 239.62M | 126.93% |
| Dec 2023 | 165504000 | 264.73M | 159.96% |
| Mar 2024 | 165272000 | 263.57M | 159.48% |
| Jun 2023 | -52.79M | 49.48M | 471K |
|---|---|---|---|
| Sep 2023 | -51.34M | 70.44M | -208K |
| Dec 2023 | -50.40M | 9.94M | 1.51M |
| Mar 2024 | -29.61M | 14.71M | 24.14M |
Atara Biotherapeutics alternative data
| Aug 2023 | 330 |
|---|---|
| Sep 2023 | 317 |
| Oct 2023 | 317 |
| Nov 2023 | 317 |
| Dec 2023 | 334 |
| Jan 2024 | 334 |
| Feb 2024 | 334 |
| Mar 2024 | 334 |
| Apr 2024 | 334 |
| May 2024 | 225 |
| Jun 2024 | 173 |
| Jul 2024 | 173 |
Atara Biotherapeutics other data
53.26%
-41.78%
of ATRA is owned by hedge funds
76
-63
54.32M
-43.02M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 56192 |
| May 2024 | 0 | 211204 |
| Aug 2024 | 0 | 8050 |
| Nov 2024 | 0 | 4028 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | HENRICH JILL officer: EVP, Chief Regulatory .. | Common Stock | 1,000 | $11.2 | $11,198 | ||
Sale | HYLLENGREN ERIC J officer: EVP, CFO and COO | Common Stock | 1,364 | $11.2 | $15,274 | ||
Sale | NGUYEN ANHCO director, officer: President an.. | Common Stock | 1,664 | $11.2 | $18,633 | ||
Sale | TOUCHON PASCAL director, officer: President an.. | Common Stock | 2,762 | $6.63 | $18,309 | ||
Sale | TOUCHON PASCAL director, officer: President an.. | Common Stock | 276 | $6.63 | $1,830 | ||
Sale | NGUYEN ANHCO officer: EVP, Chief Sci. & Tech.. | Common Stock | 1,468 | $6.63 | $9,731 | ||
Sale | NGUYEN ANHCO officer: EVP, Chief Sci. & Tech.. | Common Stock | 297 | $6.63 | $1,969 | ||
Sale | NGUYEN ANHCO officer: EVP, Chief Sci. & Tech.. | Common Stock | 56 | $6.63 | $371 | ||
Sale | MURUGAN AMAR officer: EVP, Chi.. | Common Stock | 877 | $6.63 | $5,814 | ||
Sale | MURUGAN AMAR officer: EVP, Chi.. | Common Stock | 192 | $6.63 | $1,273 |
| Quarter | Transcript |
|---|---|
| Q3 2023 4 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q3 2022 8 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 8 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 5 May 2022 | Q1 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Pascal Touchon D.V.M. (1963) Pres, Chief Executive Officer & Director | $1,090,000 |
| Dr. Kristin Yarema Ph.D. (1971) SVice President & Chief Commercial Officer | $700,670 |
Mr. Joseph Newell (1970) Executive Vice President & Chief Operating Officer | $670,380 |
| Mr. Utpal Koppikar (1971) Chief Financial Officer & SVice President | $655,450 |
| Dr. Jakob Dupont (1965) Head of Global R&D | $595,870 |
Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy
Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity
Atara Biotherapeutics: A Speculative Buy On Upcoming Phase 2 Multiple Sclerosis Readout
Atara: MS Study Data Release And Other Catalysts Make This A Must Watch
Biopharma Exposure In SVB Financial Group And Investor Strategy
Consider Atara Biotherapeutics As The Tab-Cel Delay Resolves In The U.S.
Atara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipeline
Atara: Inordinate FDA Delays Wrecked This Stock
-
What's the price of Atara Biotherapeutics stock today?
One share of Atara Biotherapeutics stock can currently be purchased for approximately $12.
-
When is Atara Biotherapeutics's next earnings date?
Unfortunately, Atara Biotherapeutics's (ATRA) next earnings date is currently unknown.
-
Does Atara Biotherapeutics pay dividends?
No, Atara Biotherapeutics does not pay dividends.
-
How much money does Atara Biotherapeutics make?
Atara Biotherapeutics has a market capitalization of 67.38M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 86.51% to 8.57M US dollars.
-
What is Atara Biotherapeutics's stock symbol?
Atara Biotherapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ATRA".
-
What is Atara Biotherapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Atara Biotherapeutics?
Shares of Atara Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Atara Biotherapeutics's key executives?
Atara Biotherapeutics's management team includes the following people:
- Dr. Pascal Touchon D.V.M. Pres, Chief Executive Officer & Director(age: 62, pay: $1,090,000)
- Dr. Kristin Yarema Ph.D. SVice President & Chief Commercial Officer(age: 54, pay: $700,670)
- Mr. Joseph Newell Executive Vice President & Chief Operating Officer(age: 55, pay: $670,380)
- Mr. Utpal Koppikar Chief Financial Officer & SVice President(age: 54, pay: $655,450)
- Dr. Jakob Dupont Head of Global R&D(age: 60, pay: $595,870)
-
How many employees does Atara Biotherapeutics have?
As Jul 2024, Atara Biotherapeutics employs 173 workers, which is 48% less then previous quarter.
-
When Atara Biotherapeutics went public?
Atara Biotherapeutics, Inc. is publicly traded company for more then 10 years since IPO on 16 Oct 2014.
-
What is Atara Biotherapeutics's official website?
The official website for Atara Biotherapeutics is atarabio.com.
-
Where are Atara Biotherapeutics's headquarters?
Atara Biotherapeutics is headquartered at 611 Gateway Boulevard, South San Francisco, CA.
-
How can i contact Atara Biotherapeutics?
Atara Biotherapeutics's mailing address is 611 Gateway Boulevard, South San Francisco, CA and company can be reached via phone at +65 02788930.
-
What is Atara Biotherapeutics stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Atara Biotherapeutics in the last 12 months, the avarage price target is $14. The average price target represents a 16.66% change from the last price of $12.
Atara Biotherapeutics company profile:
Atara Biotherapeutics, Inc.
atarabio.comExchange:
NASDAQ
Full time employees:
165
Industry:
Biotechnology
Sector:
Healthcare
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
611 Gateway Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001604464
ISIN: US0465131078
CUSIP: 046513107
